ClinicalTrials.Veeva

Menu

ONO-7913 Phase I Study (ONO-7913)

Ono Pharmaceuticals logo

Ono Pharmaceuticals

Status and phase

Completed
Phase 1

Conditions

Solid Tumor

Treatments

Biological: ONO-7913

Study type

Interventional

Funder types

Industry

Identifiers

NCT04403308
ONO-7913-01

Details and patient eligibility

About

To assess the tolerability, safety, and pharmacokinetics (PK) of ONO-7913 in patients with advanced or metastatic solid cancers and explore its efficacy and biomarkers.

Enrollment

7 patients

Sex

All

Ages

20+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Patients with histologically or cytologically confirmed advanced or metastatic solid tumors
  2. ECOG Performance Status of 0-1
  3. Patients with life expectancy of at least 3 months

Exclusion criteria

  1. Patients with multiple cancers
  2. Patients with history of serious allergy

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

7 participants in 1 patient group

ONO-7913 as a Single Agent
Experimental group
Treatment:
Biological: ONO-7913

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems